Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Cash & Equivalents (2018 - 2025)

Precision Biosciences (DTIL) has disclosed Cash & Equivalents for 8 consecutive years, with $44.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Cash & Equivalents fell 54.56% to $44.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $44.9 million, a 54.56% decrease, with the full-year FY2024 number at $85.9 million, down 26.38% from a year prior.
  • Cash & Equivalents was $44.9 million for Q3 2025 at Precision Biosciences, down from $77.2 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $212.1 million in Q3 2022 to a low of $44.9 million in Q3 2025.
  • A 5-year average of $137.6 million and a median of $137.8 million in 2023 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: surged 59.98% in 2021, then crashed 54.56% in 2025.
  • Precision Biosciences' Cash & Equivalents stood at $143.7 million in 2021, then surged by 31.96% to $189.6 million in 2022, then plummeted by 38.45% to $116.7 million in 2023, then fell by 26.38% to $85.9 million in 2024, then tumbled by 47.76% to $44.9 million in 2025.
  • Per Business Quant, the three most recent readings for DTIL's Cash & Equivalents are $44.9 million (Q3 2025), $77.2 million (Q1 2025), and $85.9 million (Q4 2024).